Dr Mead on the Use of Zanubrutinib vs Ibrutinib in MCL : vim

Monica D. Mead, MD, discusses the efficacy and safety differences between the second-generation BTK inhibitor zanubrutinib and the first-generation BTK inhibitor ibrutinib in patients with mantle cell lymphoma.

Related Keywords

Los Angeles , California , United States , Monicad Mead , , University Of California , Jonsson Comprehensive Cancer Center , Hematologic Malignancy , Comprehensive Cancer Center , D , Ucla Jonsson Comprehensive Cancer Center ,